Strategies to optimize expedited investigational new drug safety reports
Crossref DOI link: https://doi.org/10.1038/nrclinonc.2016.42
Published Online: 2016-03-21
Published Print: 2016-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Tsimberidou, Apostolia M.
Text and Data Mining valid from 2016-03-21
Article History
First Online: 21 March 2016
Competing interests
: A.M.T. receives research funding from Baxalta, Bayer, EMD Serono, Foundation Medicine, and Onyx Pharmaceuticals.